Alphatec Holdings, Inc. (NASDAQ:ATEC) Shares Sold by Stifel Financial Corp

Stifel Financial Corp lowered its position in Alphatec Holdings, Inc. (NASDAQ:ATEC - Free Report) by 13.7% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 154,167 shares of the medical technology company's stock after selling 24,535 shares during the quarter. Stifel Financial Corp owned about 0.11% of Alphatec worth $1,415,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the stock. Congress Asset Management Co. grew its position in Alphatec by 235.4% in the fourth quarter. Congress Asset Management Co. now owns 434,966 shares of the medical technology company's stock worth $3,993,000 after acquiring an additional 305,296 shares in the last quarter. Barclays PLC grew its holdings in shares of Alphatec by 362.3% during the 3rd quarter. Barclays PLC now owns 170,546 shares of the medical technology company's stock worth $948,000 after acquiring an additional 133,653 shares during the period. Rhumbline Advisers boosted its holdings in shares of Alphatec by 1.3% during the 4th quarter. Rhumbline Advisers now owns 139,088 shares of the medical technology company's stock valued at $1,277,000 after buying an additional 1,746 shares in the last quarter. Russell Investments Group Ltd. lifted its holdings in shares of Alphatec by 20.0% during the fourth quarter. Russell Investments Group Ltd. now owns 199,886 shares of the medical technology company's stock valued at $1,835,000 after purchasing an additional 33,362 shares during the last quarter. Finally, Nisa Investment Advisors LLC grew its stake in shares of Alphatec by 973.3% in the fourth quarter. Nisa Investment Advisors LLC now owns 4,669 shares of the medical technology company's stock worth $43,000 after acquiring an additional 4,234 shares during the last quarter. Hedge funds and other institutional investors own 66.35% of the company's stock.

Alphatec Stock Performance

Shares of NASDAQ:ATEC traded down $0.52 on Friday, hitting $12.22. 1,888,232 shares of the company were exchanged, compared to its average volume of 2,046,862. The stock's 50 day moving average price is $10.50 and its 200 day moving average price is $10.13. The company has a current ratio of 2.32, a quick ratio of 1.15 and a debt-to-equity ratio of 30.21. The firm has a market capitalization of $1.79 billion, a P/E ratio of -9.55 and a beta of 1.06. Alphatec Holdings, Inc. has a 1-year low of $4.88 and a 1-year high of $12.82.

Alphatec (NASDAQ:ATEC - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The medical technology company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.23). Alphatec had a negative net margin of 31.06% and a negative return on equity of 541.39%. The business had revenue of $169.18 million during the quarter, compared to analysts' expectations of $167.57 million. During the same period in the previous year, the company posted ($0.34) earnings per share. Alphatec's revenue for the quarter was up 22.2% compared to the same quarter last year. Sell-side analysts predict that Alphatec Holdings, Inc. will post -1.08 EPS for the current year.

Wall Street Analyst Weigh In

ATEC has been the topic of a number of recent analyst reports. Barclays raised their price target on shares of Alphatec from $20.00 to $21.00 and gave the company an "overweight" rating in a report on Wednesday, January 22nd. Piper Sandler restated an "overweight" rating and issued a $15.00 price objective (up from $13.00) on shares of Alphatec in a research report on Friday, May 2nd. StockNews.com raised Alphatec from a "sell" rating to a "hold" rating in a report on Friday, February 28th. HC Wainwright reissued a "buy" rating and set a $20.00 price target on shares of Alphatec in a research note on Monday, April 14th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $16.00 price objective on shares of Alphatec in a research report on Friday, May 2nd. Two analysts have rated the stock with a hold rating and eight have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $17.89.

Insider Transactions at Alphatec

In related news, EVP David Sponsel sold 33,732 shares of the business's stock in a transaction on Thursday, March 6th. The stock was sold at an average price of $10.83, for a total value of $365,317.56. Following the sale, the executive vice president now owns 668,977 shares in the company, valued at approximately $7,245,020.91. The trade was a 4.80 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Scott Lish sold 12,000 shares of the business's stock in a transaction dated Monday, May 5th. The stock was sold at an average price of $12.12, for a total transaction of $145,440.00. Following the sale, the chief operating officer now owns 826,251 shares in the company, valued at $10,014,162.12. This trade represents a 1.43 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 126,945 shares of company stock valued at $1,416,352 over the last 90 days. Corporate insiders own 20.90% of the company's stock.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.